Continue reading

Refine your search

Find a multiple myeloma clinical trial

    You can refine your search by selecting “Advanced filters”
    Location
      Status
      Sex
      Age

      Advanced filters

      8 trials found

      Recruiting (8)
      Not yet recruiting
      4 trials recruiting
      1 trial not yet recruiting
      MagnetisMM Clinical Trials

      These studies will evaluate the safety and effectiveness of a study medicine, called elranatamab, in people with multiple myeloma.

      Recruiting
      NCT06152575
      MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

      Multiple Myeloma

      Male or Female
      18+ years
      235study location(s)
      Recruiting
      NCT05317416
      Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

      Multiple Myeloma

      Male or Female
      18+ years
      223study location(s)
      Recruiting
      NCT05675449
      A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

      Multiple Myeloma

      Male or Female
      18+ years
      32study location(s)
      Recruiting
      NCT05623020
      A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, Lenalidomide or Elranatamab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

      Multiple Myeloma

      Male or Female
      18+ years
      66study location(s)
      Recruiting
      NCT06215118
      A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

      Multiple Myeloma

      Male or Female
      18+ years
      35study location(s)
      Recruiting
      NCT05020236
      A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

      Multiple Myeloma

      Male or Female
      18+ years
      238study location(s)
      Recruiting
      NCT06057402
      Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

      Multiple Myeloma

      Male or Female
      18+ years
      19study location(s)
      Recruiting
      NCT05742217
      A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases

      Relapse Multiple Myeloma, Refractory Multiple Myeloma

      Male or Female
      18+ years
      1study location(s)

      Saved trials

      Saved trials

      You currently don’t have any saved trials. To save a trial, select the bookmark icon on the result listing.

      Recruiting (8)
      Not yet recruiting

      Contact us

      For more information about participation in a Pfizer clinical trial, please email or call the Pfizer Clinical Trial Contact Center at 1-800-887-7002.

      About multiple myeloma

      Plasma cells are produced in healthy bone marrow. Plasma cells are a type of white blood cell that creates antibodies. These antibodies help your body kill germs and fight infection.

      Multiple myeloma is a type of blood cancer that forms in bone marrow. Multiple myeloma is when healthy plasma cells change and grow at a rapid pace. Abnormal (myeloma or cancer) plasma cells overcrowd and/or prevent the growth and creation of healthy plasma cells and other cells within the bone marrow.

      Like healthy plasma cells, some myeloma cells create antibodies. However, the antibodies don’t work properly, lowering your body’s ability to fight infection. Abnormal plasma cells also build up in the bones and organs, making it difficult for them to work properly, causing issues such as kidney problems.

      Continue reading